Careful Selection of Ovarian Cancer Patients for Chemo Before Surgery May Improve Survival Rates

Careful Selection of Ovarian Cancer Patients for Chemo Before Surgery May Improve Survival Rates
The use of neoadjuvant chemotherapy (NACT), or chemo administered before surgery, in patients with ovarian cancer has increased as an alternative to primary cytoreductive surgery (PCS), performed when a woman is diagnosed. But in women with stage 3C disease, NACT correlates with shorter overall survival compared to surgery, according to a recent study published in the Journal of Clinical Oncology. However, the study, "Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer," from the University of Texas MD Anderson Cancer Center, shows that women with stage IV disease have similar survival rates but lower hospital readmission rates when treated with NACT, suggesting that ovarian cancer patients should be carefully selected to receive either neoadjuvant chemotherapy or surgery. In 2010, two clinical trials revealed that women with stages 3 and 4 ovarian cancer who receive NACT have similar progression-free survival and overall survival, and less treatment-related side effects and mortality compared to those who receive PCS. However, few studies have examined the impact these trials had on the use of NACT in clinical practice, and those that did reported opposing findings. In this study, the researchers examined the use of NACT in 1,538 women with stage 3C and 4 ovarian cancer diagnosed between 2003 and 2012 in six comprehensive cancer centers. The outcomes associated with NACT, including overall survival, morbidity, and postoperative residual disease, were also analyzed in a matched sample
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *